Search | Clinical Trials Finder

Conditions: Rhinitis, Allergic, Perennial
Interventions: Fluticasone furoate nasal spray, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 12
States / cities: Baltimore, Maryland • Wheaton, Maryland • North Dartmouth, Massachusetts + 9 more

Conditions: Idiopathic Pulmonary Fibrosis, Fibrosis, Idiopathic Interstitial Pneumonias, Pathologic Processes, Lung Diseases, Interstitial, Lung Diseases, Respiratory Tract Diseases
Interventions: CC-90001, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 40 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 21
States / cities: Loma Linda, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo, Hydrochlorothiazide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Anaheim, California • Lomita, California • Miami, Florida + 5 more

Conditions: Diabetic Kidney Disease (DKD)
Interventions: CSL346, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 25 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 22
States / cities: Covina, California • Fresno, California • Lomita, California + 15 more

Conditions: Type 2 Diabetes Mellitus
Interventions: BIOD-531, Humalog Mix 75/25, Humulin R U-500; Drug
Lead sponsor: Biodel; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes, Type 1, Diabetes, Type 2
Interventions: Technosphere® Insulin Inhalation Powder, Usual Care; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2,053 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 82
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more

Conditions: Healthy
Interventions: MOA-728; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Overweight, Diabetes, PreDiabetes, Obesity
Interventions: Gelesis200, Placebo; Device
Lead sponsor: Gelesis, Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: Birmingham, Alabama • Bradenton, Florida • Miami, Florida + 9 more

Conditions: Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Interventions: Placebo Matching Mitapivat, Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: La Jolla, California • Palo Alto, California • Boston, Massachusetts + 3 more

Conditions: Chronic Pain
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Torrance, California

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and simvastatin, Simvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 50
States / cities: Huntsville, Alabama • Chandler, Arizona • Scottsdale, Arizona + 47 more

Conditions: Metastatic Colorectal Cancer, Colorectal Cancer
Interventions: MORAb-004, Placebo, Best supportive care; Drug · Other
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 67
States / cities: Alhambra, California • Bakersfield, California • Burbank, California + 54 more

Conditions: Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease
Interventions: Tolvaptan (OPC-41061), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 82
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 73 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: TD-4208, Tiotropium; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Easley, South Carolina

Conditions: Heart Failure, Healthy Volunteer
Interventions: AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more

Conditions: Peripheral Neuropathy, Neuropathic Pain
Interventions: ADL5859, Duloxetine, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Riverside, California • Torrance, California • Kissimmee, Florida + 21 more

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 27
States / cities: Goodyear, Arizona • Peoria, Arizona • Huntington Beach, California + 22 more

Conditions: Pancreatic Cancer
Interventions: ABBV-927, Budiglimab, modified FOLFIRINOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Aurora, Colorado • Baltimore, Maryland • Cleveland, Ohio + 1 more

Conditions: Low Back Pain
Interventions: Buprenorphine transdermal system, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 86
States / cities: Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more

Conditions: Dupuytren's Contracture
Interventions: collagenase clostridium histolyticum, Placebo; Biological
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more

Conditions: Prurigo Nodularis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 18 more

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Interventions: PQ Grass, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 33
States / cities: Centennial, Colorado • Denver, Colorado • Lexington, Kentucky + 27 more

Conditions: COVID-19
Interventions: Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment; Biological · Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more

Search by objective public record fields.

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)